CompletedEUCTR 2007-002111-82
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) i...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesADHD
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Belgium · Denmark and 7 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 300
- Sponsor
- Janssen-Cilag International N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, United Kingdom, Belgium, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2007-002111-82
- Official title
Show the full official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) i...
Recruitment & locations
CompletedBelgium · Denmark · Finland
6 more locations
- France
- Germany
- Netherlands
- Spain
- Sweden
- United Kingdom
Registry details
Historical country statuses
- Belgium — Completed
- Germany — Completed
- Denmark — Completed
- Spain — Completed
- Finland — Completed
- France — Completed
- United Kingdom — Completed
- Netherlands — Completed
- Sweden — Completed
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Cilag International N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...